Compare Illumina, Inc. (ILMN) vs Sunrun Inc (RUN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Sunrun Inc — how do they compare? Illumina, Inc. trades at $193.06 (market cap $28.96B), while Sunrun Inc trades at $10.06 (market cap $2.38B). The key difference: Illumina, Inc. is far larger — about 12.2× Sunrun Inc's market cap, and Illumina, Inc. is trading nearer its 52-week high, Sunrun Inc nearer its low. Which is the better fit depends on your goals.
| ILMN | RUN | |
|---|---|---|
Market Cap | $28.96B | $2.38B |
Sector | Health | Technology |
52-Week High | $205.10 | $21.41 |
52-Week Low | $91.00 | $9.38 |
Enterprise Value | $30.32B | $16.90B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $187.96, down 2.97% on the day, but maintains strong fundamental momentum with three consecutive quarterly earnings beats. The stock shows robust profitability with 66.38% gross margins and 18.34% net income margins, though technical indicators suggest near-term bearish pressure. Recent institutional buying activity and positive analyst coverage (51% buy ratings) support the stock's long-term growth narrative in the genomics sector.
The outlook remains positive with a consensus price target of $201.58 representing 7% upside potential. Key catalysts include continued NovaSeq X adoption and AI partnerships, while risks involve competitive pressures and execution challenges in achieving projected revenue growth. The company's turnaround from net losses to $850M profit in 2025 demonstrates improved operational efficiency.
Sunrun (RUN) trades at $10.20, up 8.74% in 24 hours, with a bearish technical signal and mixed sentiment. The company reported Q2 2026 EPS of $0.42, beating estimates, but shares fell due to guidance cuts. Valuation ratios appear attractive with a P/E of 6.71 and P/S of 0.77, while net income margin stands at 11.59%.
Outlook is cautious; analyst consensus is bullish with a $14.38 price target, but risks include negative operating cash flow, high debt, and competitive pressures. Near-term performance hinges on execution amid sector volatility and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Sunrun Inc
Sunrun Inc. is one of the largest residential solar, battery storage, and energy services companies in the United States. The company provides solar panel installations, battery backup systems, and energy management solutions to homeowners. Sunrun primarily uses a solar-as-a-service model, offering customers solar leases and power purchase agreements (PPAs), which allow homeowners to adopt solar energy with little to no upfront cost. The company's mission is to create a planet run by the sun.
Read more on RUN →
